133 related articles for article (PubMed ID: 9409265)
1. Induction of vascular SMC proliferation by urokinase indicates a novel mechanism of action in vasoproliferative disorders.
Kanse SM; Benzakour O; Kanthou C; Kost C; Lijnen HR; Preissner KT
Arterioscler Thromb Vasc Biol; 1997 Nov; 17(11):2848-54. PubMed ID: 9409265
[TBL] [Abstract][Full Text] [Related]
2. The catalytic domain of endogenous urokinase-type plasminogen activator is required for the mitogenic activity of platelet-derived and basic fibroblast growth factors in human vascular smooth muscle cells.
Padró T; Mesters RM; Dankbar B; Hintelmann H; Bieker R; Kiehl M; Berdel WE; Kienast J
J Cell Sci; 2002 May; 115(Pt 9):1961-71. PubMed ID: 11956327
[TBL] [Abstract][Full Text] [Related]
3. Urokinase-induced smooth muscle cell responses require distinct signaling pathways: a role for the epidermal growth factor receptor.
Nicholl SM; Roztocil E; Davies MG
J Vasc Surg; 2005 Apr; 41(4):672-81. PubMed ID: 15874933
[TBL] [Abstract][Full Text] [Related]
4. Contrasting effects of plasminogen activators, urokinase receptor, and LDL receptor-related protein on smooth muscle cell migration and invasion.
Okada SS; Grobmyer SR; Barnathan ES
Arterioscler Thromb Vasc Biol; 1996 Oct; 16(10):1269-76. PubMed ID: 8857924
[TBL] [Abstract][Full Text] [Related]
5. Vitronectin concentrates proteolytic activity on the cell surface and extracellular matrix by trapping soluble urokinase receptor-urokinase complexes.
Chavakis T; Kanse SM; Yutzy B; Lijnen HR; Preissner KT
Blood; 1998 Apr; 91(7):2305-12. PubMed ID: 9516128
[TBL] [Abstract][Full Text] [Related]
6. Domain-dependent action of urokinase on smooth muscle cell responses.
Tanski WJ; Fegley AJ; Roztocil E; Davies MG
J Vasc Surg; 2004 Jan; 39(1):214-22. PubMed ID: 14718842
[TBL] [Abstract][Full Text] [Related]
7. Urokinase receptor-dependent upregulation of smooth muscle cell adhesion to vitronectin by urokinase.
Chang AW; Kuo A; Barnathan ES; Okada SS
Arterioscler Thromb Vasc Biol; 1998 Dec; 18(12):1855-60. PubMed ID: 9848876
[TBL] [Abstract][Full Text] [Related]
8. Urokinase plasminogen activator induces human smooth muscle cell migration and proliferation via distinct receptor-dependent and proteolysis-dependent mechanisms.
Stepanova V; Mukhina S; Köhler E; Resink TJ; Erne P; Tkachuk VA
Mol Cell Biochem; 1999 May; 195(1-2):199-206. PubMed ID: 10395084
[TBL] [Abstract][Full Text] [Related]
9. Augmented urokinase receptor expression in atheroma.
Noda-Heiny H; Daugherty A; Sobel BE
Arterioscler Thromb Vasc Biol; 1995 Jan; 15(1):37-43. PubMed ID: 7749814
[TBL] [Abstract][Full Text] [Related]
10. Structural requirements for the growth factor activity of the amino-terminal domain of urokinase.
Rabbani SA; Mazar AP; Bernier SM; Haq M; Bolivar I; Henkin J; Goltzman D
J Biol Chem; 1992 Jul; 267(20):14151-6. PubMed ID: 1321137
[TBL] [Abstract][Full Text] [Related]
11. Urokinase plasminogen activator induces smooth muscle cell migration: key role of growth factor-like domain.
Stepanova V; Bobik A; Bibilashvily R; Belogurov A; Rybalkin I; Domogatsky S; Little PJ; Goncharova E; Tkachuk V
FEBS Lett; 1997 Sep; 414(2):471-4. PubMed ID: 9315743
[TBL] [Abstract][Full Text] [Related]
12. Heparin selectively inhibits the transcription of tissue-type plasminogen activator in primate arterial smooth muscle cells during mitogenesis.
Au YP; Kenagy RD; Clowes AW
J Biol Chem; 1992 Feb; 267(5):3438-44. PubMed ID: 1310687
[TBL] [Abstract][Full Text] [Related]
13. Gene transfer of the urokinase-type plasminogen activator receptor-targeted matrix metalloproteinase inhibitor TIMP-1.ATF suppresses neointima formation more efficiently than tissue inhibitor of metalloproteinase-1.
Lamfers ML; Grimbergen JM; Aalders MC; Havenga MJ; de Vries MR; Huisman LG; van Hinsbergh VW; Quax PH
Circ Res; 2002 Nov; 91(10):945-52. PubMed ID: 12433840
[TBL] [Abstract][Full Text] [Related]
14. Chemotactic effect of urokinase plasminogen activator: a major role for mechanisms independent of its proteolytic or growth factor domains.
Poliakov AA; Mukhina SA; Traktouev DO; Bibilashvily RS; Gursky YG; Minashkin MM; Stepanova VV; Tkachuk VA
J Recept Signal Transduct Res; 1999 Nov; 19(6):939-51. PubMed ID: 10533982
[TBL] [Abstract][Full Text] [Related]
15. Differential regulation of urokinase-type plasminogen activator expression by basic fibroblast growth factor and serum in myogenesis. Requirement of a common mitogen-activated protein kinase pathway.
Miralles F; Ron D; Baiget M; Félez J; Muñoz-Cánoves P
J Biol Chem; 1998 Jan; 273(4):2052-8. PubMed ID: 9442043
[TBL] [Abstract][Full Text] [Related]
16. Urokinase plasminogen activator augments cell proliferation and neointima formation in injured arteries via proteolytic mechanisms.
Plekhanova O; Parfyonova Y; Bibilashvily R; Domogatskii S; Stepanova V; Gulba DC; Agrotis A; Bobik A; Tkachuk V
Atherosclerosis; 2001 Dec; 159(2):297-306. PubMed ID: 11730809
[TBL] [Abstract][Full Text] [Related]
17. The urokinase-type plasminogen activator receptor mediates tyrosine phosphorylation of focal adhesion proteins and activation of mitogen-activated protein kinase in cultured endothelial cells.
Tang H; Kerins DM; Hao Q; Inagami T; Vaughan DE
J Biol Chem; 1998 Jul; 273(29):18268-72. PubMed ID: 9660790
[TBL] [Abstract][Full Text] [Related]
18. Urokinase receptor expression on human microvascular endothelial cells is increased by hypoxia: implications for capillary-like tube formation in a fibrin matrix.
Kroon ME; Koolwijk P; van der Vecht B; van Hinsbergh VW
Blood; 2000 Oct; 96(8):2775-83. PubMed ID: 11023511
[TBL] [Abstract][Full Text] [Related]
19. Release of soluble urokinase receptor from vascular cells.
Chavakis T; Willuweit AK; Lupu F; Preissner KT; Kanse SM
Thromb Haemost; 2001 Aug; 86(2):686-93. PubMed ID: 11522023
[TBL] [Abstract][Full Text] [Related]
20. Urokinase activates the Jak/Stat signal transduction pathway in human vascular endothelial cells.
Dumler I; Kopmann A; Weis A; Mayboroda OA; Wagner K; Gulba DC; Haller H
Arterioscler Thromb Vasc Biol; 1999 Feb; 19(2):290-7. PubMed ID: 9974409
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
